Clinical Trial Liability Insurance

Clinical Trial Liability Insurance

Written and reviewed by Michael LaBarbera, licensed insurance agent· License numbers available on request· Last reviewed October 17, 2026

Trial liability and subject injury compensation coverage for clinical research sponsors and sites.

Clinical trial liability insurance covers claims by research participants alleging bodily injury or protocol-related harm, along with defense costs. Sponsors, contract research organizations, investigators and research sites buy it, often because ethics committees, trial agreements or foreign regulators require evidence of coverage before enrolling subjects.

Clinical trial liability key facts
Informed consent ruleFDA informed consent requirements for human subjects are in 21 CFR Part 50. (21 CFR Part 50)
Injury disclosureConsent must explain whether compensation and medical treatment are available if injury occurs. (FDA informed consent guidance)
Exculpatory languageConsent forms may not ask subjects to waive legal rights or release sponsors from liability. (21 CFR Part 50)
Policy basisTypically claims-made, covering the sponsor's and sites' liability to subjects.
Foreign requirementsSome countries mandate local insurance certificates, which vary by country; check each.
Typical buyersSponsors, CROs, investigators, academic sites and device or biotech startups.
Product coverageMarketed-product liability is a separate exposure from trial liability.

What is clinical trial liability insurance?

Clinical trial liability insurance responds when a participant alleges that taking part in a study caused injury. It typically pays defense costs and covered damages arising from the conduct of the trial, including claims about the investigational product, protocol design or the way the study was run.

The policy is usually bought by the sponsor, who owns the study, and may name investigators, sites and sometimes CROs as insureds. Sites and academic institutions often carry their own professional liability, which may not extend to sponsor-designed protocols.

There is an important distinction between liability insurance and a promise to pay medical expenses regardless of fault. A study agreement or consent document may make commitments that a liability policy does not fund. Reconcile those documents before enrollment rather than assuming all participant compensation belongs under one policy. Ask how emergency treatment, expenses incurred without prior approval and claims arising after a participant withdraws are handled under the actual proposed wording.

Why do sponsors and sites need it?

Participants are exposed to unproven interventions, and the legal standard for informed consent is demanding. FDA rules require that subjects receive information about risks, alternatives and whether compensation or treatment is available for injury, and they prohibit language that waives a subject's legal rights.

Beyond liability itself, contracts drive purchasing. Clinical trial agreements, institutional review boards and foreign health authorities often require proof of insurance before the first participant is enrolled. A lack of coverage can delay a study, even if no claim ever arises.

Inventory each party's responsibilities, including product supply, randomization, monitoring, laboratory services and safety reporting. A contract may allocate responsibility for those tasks without making the responsible party an insured. Obtain the policy's insured definition and endorsements, not just a certificate. Also distinguish sponsor indemnification obligations from insurance protection: a broad contractual promise can remain the sponsor's financial responsibility if the policy excludes the assumed obligation or the indemnified party is outside its scope.

How does a policy respond to a claim?

A participant, or a family, notifies the sponsor or site of alleged harm, and the policy's claims-made trigger usually requires that the claim be reported during the policy period or an extended reporting period. The carrier typically appoints defense counsel and evaluates whether the injury arose from the covered study.

Long-tailed injuries are a design issue: harm can appear years after dosing. Because of that, sponsors should discuss tail coverage, how long the policy remains available after the study ends and how the retroactive date interacts with enrollment dates.

For example, a participant may allege injury after an eligibility check missed a contraindication, with the sponsor and investigator disputing responsibility for the screening criteria. This is an illustrative claim, not a documented loss. Preserve the protocol version, enrollment records and consent materials, then notify the appropriate carriers. Whether ordinary professional liability, trial liability or both respond depends on the pleaded allegations and how the policies divide investigational care from routine clinical treatment.

What should buyers check before purchasing?

Confirm the geography of the sites, as some countries require locally issued policies. Review how the policy defines a covered trial, whether phases I through IV are handled, and whether decentralized or telehealth components are included. Check no-fault compensation arrangements and whether they are insured separately.

Look at exclusions for known protocol deviations, unapproved changes and manufacturing defects. Get competing quotes from up to 10 carriers through our agency.

A multinational study should have an insurance schedule matching enrollment dates and locations, with responsibility for renewal assigned to a named team member. Adding a country, increasing enrollment or changing a protocol can require insurer review. Discuss whether a local certificate is sufficient or whether an issued local policy is necessary. Record retention and a stable reporting contact also matter after the study closes, when staff changes can otherwise delay notification of a participant's claim.

What it typically responds to

  • Participant bodily injury. Claims alleging injury from participation in the covered study.
  • Protocol-related claims. Allegations about study design, monitoring or conduct.
  • Informed consent allegations. Claims that risks were not adequately disclosed.
  • Investigator and site liability. Named investigators and sites where included as insureds.
  • Defense costs. Legal defense of covered participant claims.

Common exclusions

  • Unapproved protocol changes. Deviations made without required approvals may be excluded.
  • Marketed-product liability. Post-approval product claims are a separate exposure.
  • Known injuries. Events known before policy inception are typically excluded.
  • Fraud and data falsification. Intentional misconduct is usually excluded.
  • Regulatory fines. Penalties from regulators are generally not covered.

What drives price

Trial phase
Early-phase studies with unknown safety profiles carry different risks than late-phase studies.
Participant count
More enrolled subjects increase potential exposure.
Therapeutic area
Oncology, gene therapy and psychiatric studies carry different loss profiles.
Countries and sites
Geography affects local insurance requirements and legal environments.
Vulnerable populations
Pediatric or cognitively impaired participants draw extra scrutiny.
Study duration and tail
Long follow-up and extended reporting needs affect structure.

US Professional Insure does not publish premium figures. Pricing is set by each carrier and depends on the specific risk.

Sources

  1. Electronic Code of Federal Regulations — 21 CFR Part 50 – Protection of Human Subjects
  2. U.S. Food and Drug Administration — Informed Consent: Guidance for IRBs, Clinical Investigators, and Sponsors
  3. U.S. Food and Drug Administration — Clinical Trials Guidance Documents

Questions we get asked

It generally covers liability for participant injury arising from a study, including defense costs. Coverage may extend to protocol and consent allegations. Exact scope depends on the policy wording and listed insureds.

Not by one universal federal rule, but contracts, ethics committees and many foreign authorities require it. Check each trial agreement and country requirement before enrollment.

Usually the sponsor, who often names sites and investigators as insureds. Institutions may carry their own professional liability, which may not cover sponsor-directed protocol risks.

No. FDA regulations state that informed consent may not include language that has the subject waive legal rights or releases the sponsor or investigator from liability for negligence.

Only if the claim is reported within the policy or its extended reporting period. Because injuries can emerge later, ask about tail coverage and how long it can be purchased.

Provide the protocol synopsis, phase, subject numbers, countries and consent documents. Because carriers differ by phase and geography, get competing quotes from up to 10 carriers through our agency.

Ready to price clinical trial liability?

One application, shopped to the carriers that actually write this class. A licensed agent presents the options side by side.

Get my quotes 1-866-964-6660

Mon – Fri, 8:00am – 6:00pm ET

Get quotes Call1-866-964-6660